Zealand Pharma
3 articles
Industry NewsBoehringer Ingelheim / Zealand PharmaBioSpace
Boehringer, Zealand's survodutide shows no added heart risk in Phase 3 CV safety trial
- In the Phase 3 SYNCHRONIZE-CVOT trial (5,530 adults with overweight or obesity and elevated cardiovascular risk), survodutide was non-inferior to placebo on major cardiovascular events.
- Results were presented at AHA and published in The Lancet; at 72 weeks it also lowered systolic blood pressure and waist circumference versus placebo.
- GI-related discontinuations ran about 19-21% versus 1.9% on placebo; Zealand attributes this to limited titration flexibility, and analysts flag tolerability as a liability.
- The data support global regulatory filings for obesity.
Clearing the CV safety bar de-risks filing, but survodutide arrives behind semaglutide and tirzepatide with GI discontinuations near 20%, which is hard to defend commercially. Its real differentiation is glucagon-driven liver benefit; the MASH data and any gentler titration results will decide whether it is a contender or a follower.
Industry NewsZealand Pharma / Generate BiomedicinesFierce Biotech
Zealand pays $30M upfront for Generate's AI-designed multispecific proteins in obesity
- Generate will use its AI platform to design multispecific proteins for obesity and metabolic disease, leading research to lead-candidate selection.
- Zealand then takes over clinical development, regulatory work and commercialization, starting with two programs and an option on a third.
- Reported terms: $30M upfront, up to $35M of early preclinical milestones and nearly $1.2B in total milestones plus tiered royalties.
Zealand already has Roche and Boehringer on its obesity assets, and this adds a third modality bet, AI-designed biologics, with a small upfront. The structure keeps risk on Generate until a lead exists. For Generate, it's another big-pharma-style validation after Novartis and Amgen, although multispecifics in obesity are still unproven clinically.
Industry NewsBoehringer Ingelheim / Zealand PharmaFierce Biotech
Survodutide's second underwhelming phase 3 read-out knocks Zealand's shares
- Boehringer Ingelheim and Zealand's survodutide produced weight loss of up to roughly 13% in people with diabetes in phase 3.
- Zealand's shares fell sharply after the data, which landed a day after Lilly's eloralintide–tirzepatide combination read-out.
- Gastrointestinal side effects drove about 18% of treated patients to stop, keeping tolerability in question.
- It is the second recent disappointment for the compound after earlier SYNCHRONIZE-1 data.
The efficacy sits between semaglutide 2.4 mg and top-dose tirzepatide, but timing is brutal: Lilly's amylin combination landed 24 hours earlier at a far higher weight-loss level. With roughly one in five patients dropping out on GI effects, survodutide's remaining angle is MASH, where glucagon activity is the differentiator, not raw weight loss. Expect investors to price Zealand on that liver story and on how Boehringer positions dosing and titration.